Severe Eczema: Skin Severity, Daily Burden and Treatment Response

Severe eczema is assessed through skin findings, symptoms and their effect on everyday life; a photograph or the size of a rash cannot describe all of that burden. Treatment assessment also asks what has changed since care began. These are related questions, but they are not interchangeable. This guide concerns atopic dermatitis and explains how published assessment frameworks differ, without diagnosing a rash or selecting a medicine.

NICE QS44: psychological wellbeing and quality of life · HOME: clinical trial outcome set · Sources checked September 29, 2026.

Physical severity and life disruption can differ

NICE guidance for children under 12 describes severe physical disease using features such as widespread dry skin and persistent itching, with possible skin thickening, bleeding, oozing or cracking. It separately rates effects on activities, wellbeing and sleep. Different areas of the same child's skin can have different severity.

NICE explicitly warns that physical severity and quality-of-life impact do not necessarily track each other. Its quality standard therefore asks about the child and family at each eczema consultation, including when the skin appears mildly affected. A description of limited visible disease should not erase a report of major disruption. These are pediatric assessment statements, not an adult scoring rule.

NICE CG57: assessment in children under 12 · NICE QS44: psychological wellbeing and quality of life · Sources checked September 29, 2026.

Which part of eczema does each measure describe?

The HOME initiative separates clinical-trial outcomes into clinical signs, patient-reported symptoms, long-term control and quality of life. EASI, the Eczema Area and Severity Index, measures signs; POEM, the Patient-Oriented Eczema Measure, records symptoms. RECAP or ADCT addresses control. Quality-of-life instruments differ for adults, children and infants.

Our comparison uses those separate domains as a reading rule: a better skin-sign score does not, by itself, report better sleep, less itch or sustained control. Those outcomes require their own observations. The HOME set is a framework for trials; it is not a home diagnostic checklist, and it does not make the instruments substitutes for one another.

HOME: clinical trial outcome set · Sources checked September 29, 2026.

A response threshold is not a definition of severe eczema

An adult treatment appraisal illustrates the distinction. NICE TA534 specifies a response review at 16 weeks for dupilumab: its adequate-response criterion requires both at least a 50% reduction in EASI and at least a 4-point reduction in the Dermatology Life Quality Index, measured from treatment start. The appraisal also specifies prior systemic-treatment failure, intolerance or contraindication and a commercial arrangement for access.

That is a particular UK treatment and funding framework for adults. It is not a US eligibility rule, a universal definition of severe disease or an instruction to stop an individual's prescription. The percentage describes change from baseline, not the percentage of a person's skin that has cleared. Meeting a response criterion also does not establish that symptoms have disappeared.

Read the decision in order: whose care is being assessed, which treatment and jurisdiction apply, what the starting measures were, and which outcomes must improve. A severity label at the first visit and a response assessment later in treatment answer different questions.

NICE TA534: adult dupilumab recommendations · Sources checked September 29, 2026.

Severe does not name a single next medicine

The American Academy of Dermatology's adult guidelines include systemic medicines and phototherapy, with recommendations of different strengths. They recommend against systemic corticosteroids. That statement concerns medicines acting throughout the body; it should not be read as a prohibition on topical corticosteroid treatment. The guideline page separately addresses topical treatments and subsequent updates.

The useful distinction is between assessing disease burden and choosing treatment. Neither a severity adjective nor an isolated research endpoint identifies a suitable drug for an individual. Medication history, response, risks and the applicable clinical guidance remain part of the clinician's decision.

AAD: atopic dermatitis clinical guidelines · Sources checked September 29, 2026.

Keep the baseline and the review comparable

For a review conversation, separate what the skin looks and feels like from how eczema interrupts ordinary life. Keep the date and the instrument name with any formal score. Report what remains difficult even when one measure improves; a clinician can interpret the different signals together.

The practical output is a record of burden and change, not a self-assigned severity grade. This page does not identify a food trigger, propose an elimination diet or promise that a supplement treats severe eczema. Its narrower purpose is to make the assessment language readable without turning a trial measure or a treatment rule into a diagnosis.

HOME: clinical trial outcome set · NICE QS44: psychological wellbeing and quality of life · Sources checked September 29, 2026.

Reviewed September 29, 2026. Educational analysis; not individualized medical advice.